AI Article Synopsis
- Trimodal therapy is a new treatment for bladder cancer that combines surgery, radiation, and chemotherapy instead of removing the bladder completely.
- Using special chemotherapy with radiation helps control cancer better than just radiation alone.
- There are different methods and doses used around the world, but doctors are working on improving these treatments and testing new combinations to help patients even more.
Article Abstract
Trimodal therapy consisting of transurethral resection of bladder tumors followed by radiotherapy and chemotherapy, has emerged as a valuable therapeutic alternative to radical cystectomy in patients with muscle invasive bladder cancer. Concomitant radiosensitising chemotherapy is a component of trimodality increasing locoregional control compared to radiotherapy alone. The combinations 5-fluorouracil with mitomycin or cisplatin are the best supported in the literature. Gemcitabine appears to be a feasible and promising alternative. There is considerable international heterogeneity in terms of dose, volumes and fractionation. The most commonly used regimens are moderately hypofractionated (55Gy in 20 fractions over 4 weeks) and normofractionated (64Gy in 32 fractions) regimens. Radiotherapy for bladder cancer is an effective and evolving treatment, with current technical developments, and studies of new combinations with systemic treatments underway.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.canrad.2024.08.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!